Identification of short peptides: optimization of target therapeutic properties of the thymus medicine
Laboratory analysis · 2021
- What was studied
- Thymalin composition by UHPLC–MS
- Main finding
- Identifies KE and EDP as minor components of Thymalin and cites earlier detection of EW. KE maps to Vilon; EW maps to Thymogen in the short-peptide catalogue.
Study data at a glance
- Participants or experimental model
- Thymalin composition by UHPLC–MS
- Reported results
- Identifies KE and EDP as minor components of Thymalin and cites earlier detection of EW. KE maps to Vilon; EW maps to Thymogen in the short-peptide catalogue.
Study limitations and source details
Study limitations
- EW identification is cited earlier work, not a new EW experiment in this report.
- Presence in the extract does not assign all extract benefits to individual sequences.
Source details
Publisher English abstract and reference list checked.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
V. Kh. Khavinson, I. K. Zhurkovich, G. A. Ryzhak, E. S. Mironova, N. G. Kovrov. Identification of short peptides: optimization of target therapeutic properties of the thymus medicine Molecular Medicine, 2021
Study source ↗ · DOI 10.29296/24999490-2021-03-05 · Bibliography entry · Link to this summary
Related compounds
Thymalin
A mixture of polypeptides extracted from bovine thymus. Human studies examined immune-cell measures and infection outcomes during adjunctive treatment.
Vilon
A synthetic two-amino-acid peptide (Lys–Glu, or KE) studied in thymus, immune and tissue-repair research.
Thymogen
A synthetic dipeptide, α-L-glutamyl-L-tryptophan (Glu–Trp, EW). Its alpha peptide bond and L-amino acids distinguish it from the gamma-linked immune peptides Bestim and Thymodepressin.